Autolus Therapeutics (AUTL) Earnings Date & Reports
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer... Show more
AUTL is expected to report earnings to rise 13.33% to -17 cents per share on October 29
Q3'26
Est.
$-0.17
Q2'26
Beat
by $0.08
Q1'26
Missed
by $0.02
Q4'25
Missed
by $0.09
Q3'25
Missed
by $0.08
The last earnings report on August 11 showed earnings per share of -15 cents, beating the estimate of -23 cents. With 1.32M shares outstanding, the current market capitalization sits at 641.45M.